Ticker LaunchIPO · LVTX
LAVA Therapeutics NV
Formerly LAVA Therapeutics BV
LAVA Therapeutics NV (LVTX) priced its initial public offering on Mar 26, 2021 at $15.00 per share, within its $14.00–$16.00 range, raising $100.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $380.3M. J.P. Morgan was lead-left underwriter, joined by Jefferies and Leerink Partners. Davis Polk advised the underwriters.
- Status
- IPO
- Ticker
- LVTX
- Exchange
- Nasdaq Global Select
- Priced
- Mar 26, 2021
- IPO price
- $15.00
- Price range
- $14.00–$16.00
- Raised
- $100.5M
- Market cap at IPO price
- $380.3M
- First filed
- Mar 2, 2021
- Underwriters
- J.P. Morgan, Jefferies and Leerink Partners
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Mar 2, 2021
- Latest amendment Mar 24, 2021
- Final prospectus (424B4) Mar 26, 2021
- All filings on EDGAR CIK 1840748
Other Biotech & pharma IPOs in 2021
- Design Therapeutics, Inc.DSGN · Mar 26, 2021 · $240M
- Edgewise Therapeutics, Inc.EWTX · Mar 26, 2021
- ImageneBio, Inc.IKNA · Mar 26, 2021 · $125M
- Universe Pharmaceuticals INCUPC · Mar 24, 2021 · $25M
- Finch Therapeutics Group, Inc.FNCH · Mar 22, 2021 · $127.5M
- Gain Therapeutics, Inc.GANX · Mar 22, 2021 · $40M